PHIO — Phio Pharmaceuticals Corp.

Is PHIO overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of October 3, 2026

Phio Pharmaceuticals Corp. (PHIO) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $0.99. The rating moved from Neutral to Oversold on October 2, 2026.

See all oversold Healthcare stocks →

AI analysis

Phio Pharmaceuticals Corp. (PHIO) is an early-stage biotech whose market value depends heavily on upcoming clinical readouts and deal flow. In the current cautious market backdrop, limited liquidity and likely constrained capital access increase the odds of dilution absent a near-term positive catalyst. Potential upside is concentrated in successful clinical outcomes or partnership/licensing transactions; downside is driven by trial setbacks, cash runway shortfalls, and payer/regulatory pressures. Monitor cash disclosures, trial timelines, and any partnering news as primary indicators for directional change.

Key factors

  • Phio Pharmaceuticals Corp. (PHIO) is a small-cap, clinical-stage biopharma with limited or no recurring revenue and value tied to clinical and partnership milestones
  • Upcoming clinical data readouts or licensing deals would be primary near-term value drivers and could materially re-rate the stock
  • Market environment is risk-off (lower IPO/deal appetite) which constrains capital access for early-stage healthcare issuers and increases dilution risk
  • Regulatory and payer environment (Medicare negotiation / pricing pressure) is an ongoing headwind for specialty drug economics and commercialization prospects
  • Microcap/low-liquidity status increases intraday volatility and makes short-term price moves sensitive to news flow
  • Technology/pipeline differentiation could produce meaningful upside if clinical outcomes validate the approach or attract partners

Risks

  • Clinical trial failure or delay removing the primary path to value creation
  • Insufficient cash runway forcing dilutive financing or unfavorable licensing terms
  • Regulatory setbacks, manufacturing scale-up issues, or unfavorable review outcomes
  • Adverse changes in payer coverage or pricing (domestic and international) that limit commercial potential
  • Intense competition from better-funded peers or alternative modalities that reduce market opportunity
  • Low trading liquidity leading to outsized price moves on relatively small flows or promotional activity
  • Broader market risk-off periods and geopolitical headlines reducing investor appetite for speculative biotech names

See today's live rating, score and targets

Members see the live hourly rating for PHIO — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.